PURPOSE: To investigate the age-specific pattern of administration of chemotherapy and its association with long-term survival and quality of life (QoL) in stage II and III colorectal cancer patients. METHODS: Chemotherapy allocation according to disease and patient characteristics was investigated in a population-based cohort of 562 stage II and III colorectal cancer patients. Five years after diagnosis, survival was determined and QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items and a tumor specific module. The association among chemotherapy, survival, and QoL was examined while controlling for potential confounders. RESULTS: Chemotherapy was administered in 71% of patients aged <60 years and in only 20% of patients aged ≥80 years. A significant association between chemotherapy and longer survival time was found for stage III cancer only. Chemotherapy was associated with higher symptom levels for trouble with taste, anxiety, and hair loss. In age-specific analyses, younger survivors (<70 years at time of follow-up) with a history of chemotherapy reported significantly lower physical, role, and cognitive functioning and higher pain, appetite loss, hair loss, and trouble with taste symptom levels. In contrast, for older survivors (≥70 years), only two (hair loss and dry mouth) out of 38 QoL scores were significantly associated with chemotherapy. DISCUSSION: Chemotherapy is associated with lower long-term QoL, especially in younger survivors. In cases of uncertain survival benefits of chemotherapy, consideration of its long-term effects on QoL should be incorporated into final decisions on treatment.
PURPOSE: To investigate the age-specific pattern of administration of chemotherapy and its association with long-term survival and quality of life (QoL) in stage II and III colorectal cancerpatients. METHODS: Chemotherapy allocation according to disease and patient characteristics was investigated in a population-based cohort of 562 stage II and III colorectal cancerpatients. Five years after diagnosis, survival was determined and QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items and a tumor specific module. The association among chemotherapy, survival, and QoL was examined while controlling for potential confounders. RESULTS: Chemotherapy was administered in 71% of patients aged <60 years and in only 20% of patients aged ≥80 years. A significant association between chemotherapy and longer survival time was found for stage III cancer only. Chemotherapy was associated with higher symptom levels for trouble with taste, anxiety, and hair loss. In age-specific analyses, younger survivors (<70 years at time of follow-up) with a history of chemotherapy reported significantly lower physical, role, and cognitive functioning and higher pain, appetite loss, hair loss, and trouble with taste symptom levels. In contrast, for older survivors (≥70 years), only two (hair loss and dry mouth) out of 38 QoL scores were significantly associated with chemotherapy. DISCUSSION: Chemotherapy is associated with lower long-term QoL, especially in younger survivors. In cases of uncertain survival benefits of chemotherapy, consideration of its long-term effects on QoL should be incorporated into final decisions on treatment.
Authors: Cora L Craig; Alison L Marshall; Michael Sjöström; Adrian E Bauman; Michael L Booth; Barbara E Ainsworth; Michael Pratt; Ulf Ekelund; Agneta Yngve; James F Sallis; Pekka Oja Journal: Med Sci Sports Exerc Date: 2003-08 Impact factor: 5.411
Authors: Hermann Brenner; Jenny Chang-Claude; Christoph M Seiler; Alexander Rickert; Michael Hoffmeister Journal: Ann Intern Med Date: 2011-01-04 Impact factor: 25.391
Authors: L B Wenzel; D L Fairclough; M J Brady; D Cella; K M Garrett; B C Kluhsman; L A Crane; A C Marcus Journal: Cancer Date: 1999-11-01 Impact factor: 6.860
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg Journal: J Clin Oncol Date: 2004-04-05 Impact factor: 44.544
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Kord M Kober; Jon D Levine; Christine Miaskowski Journal: Qual Life Res Date: 2018-04-21 Impact factor: 4.147
Authors: Cedrick D Dotson; Connie L Colbert; Mircea Garcea; James C Smith; Alan C Spector Journal: Am J Physiol Regul Integr Comp Physiol Date: 2012-07-11 Impact factor: 3.619
Authors: E J Kap; P Seibold; S Richter; D Scherer; N Habermann; Y Balavarca; L Jansen; N Becker; K Pfütze; O Popanda; M Hoffmeister; A Ulrich; A Benner; C M Ulrich; B Burwinkel; H Brenner; J Chang-Claude Journal: Pharmacogenomics J Date: 2015-03-17 Impact factor: 3.550
Authors: Khaled El-Shami; Kevin C Oeffinger; Nicole L Erb; Anne Willis; Jennifer K Bretsch; Mandi L Pratt-Chapman; Rachel S Cannady; Sandra L Wong; Johnie Rose; April L Barbour; Kevin D Stein; Katherine B Sharpe; Durado D Brooks; Rebecca L Cowens-Alvarado Journal: CA Cancer J Clin Date: 2015-09-08 Impact factor: 508.702
Authors: Biljana Gigic; Johanna Nattenmüller; Martin Schneider; Yakup Kulu; Karen L Syrjala; Jürgen Böhm; Petra Schrotz-King; Hermann Brenner; Graham A Colditz; Jane C Figueiredo; William M Grady; Christopher I Li; David Shibata; Erin M Siegel; Adetunji T Toriola; Hans-Ulrich Kauczor; Alexis Ulrich; Cornelia M Ulrich Journal: Nutrients Date: 2020-04-28 Impact factor: 5.717